Bart van Hartingsveldt

Statistics

Publications

Citations

267

H-Index

Active since

1996

Affiliations

Janssen (United States)(Current)

Janssen (Belgium)

Bart van Hartingsveldt is an author at Janssen (United States) specializing in pharmacokinetics of monoclonal antibodies, pharmacology, and rheumatology.

Publications per year

1996–2013

Publications

Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Intravenous, Dose‐Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus

Jacek C. Szepietowski, Surasak Nilganuwong, Anna Woźniacka et al. · Arthritis & Rheumatism · 2013 · 112 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study

Zhenhua Xu, Esther Bouman‐Thio, Craig Comisar et al. · British Journal of Clinical Pharmacology · 2011 · 96 citations · Full text

Medicine, Immunology, Pharmacology +17

A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.

René Westhovens, Frédéric Houssiau, Johan Joly et al. · PubMed · 2006 · 22 citations

Medicine, Pharmacokinetics, Pharmacology +14

Safety, tolerability and pharmacokinetics of a human anti‐interleukin‐13 monoclonal antibody (<scp>CNTO</scp> 5825) in an ascending single‐dose first‐in‐human study

Bart van Hartingsveldt, Ivo Nnane, Esther Bouman‐Thio et al. · British Journal of Clinical Pharmacology · 2012 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Ex vivo cytokine release from whole blood

Roel P. F. Schins, Bart van Hartingsveldt, Paul J. A. Borm · Experimental and Toxicologic Pathology · 1996 · 18 citations

Life Sciences, Immunology, Physiology +13

1–5 of 5